Two major clinical trials have focused on the effectiveness of Sucraid®(sacrosidase) Oral Solution. In the first clinical trial, researchers concluded that Sucraid® is an effective and well-tolerated treatment for the deficiency of sucrase associated with Genetic Sucrase-Isomaltase Deficiency/Congenital Sucrase-Isomaltase Deficiency.1 When patients took a small amount of sacrosidase with each meal, they were able to eat a normal sucrose-containing diet without developing major gastrointestinal symptoms. Researchers also speculated that long-term sacrosidase therapy may reduce the high incidence of GI complaints in this patient population.
In the second clinical trial, researchers again found that Sucraid® is a safe, well-tolerated, and effective treatment for the gastrointestinal symptoms of Genetic Sucrase-Isomaltase Deficiency.2 Patients in this long-term study covered a broad range of ages. While taking Sucraid®, they were able to consume a sucrose-containing diet with reduced gastrointestinal symptoms associated with Genetic Sucrase-Isomaltase Deficiency.